BioSig Technologies, Inc. (NASDAQ: BSGM), a Westport, CT-based medical technology company focused on intracardiac signal visualization, closed a seed funding round raising $2.2m for BioSig AI Sciences, Inc. (BAIS).
BAIS, a majority-owned Delaware C Corporation subsidiary of BioSig, is developing AI solutions for the hospital marketplace utilizing structured, semi-structured, and unstructured data.
BioSig AI Sciences intends to join BioSig’s technology team with external partners and collaborators to advance the research and development of an artificial intelligence (“AI”) medical device platform.
Led by Ken Londoner, Chairman, CEO and Founder, BioSig Technologies is an advanced medical technology company bringing insights to the treatment of cardiovascular arrhythmias. The company’s first product, the PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.
BioSig and Reified Labs’ initial AI collaboration, which began in 2019, has resulted in multiple patent applications to date and a research publication on AI-enhanced electrocardiogram lead placement mapping. The renewed collaboration, BAIS, is also looking into the application of Chat-GPT like large language models and how they apply to helping our hospital partners leverage such technology to solve the myriad of challenges they currently face.
FinSMEs
25/07/2023